Search

Your search keyword '"García Navalón, Francisco Javier"' showing total 6 results
Start Over Author "García Navalón, Francisco Javier"
6 results on '"García Navalón, Francisco Javier"'

1. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry

Author

Arias-Martinez, Aranzazu, Martínez de Castro, Eva, Gallego, Javier, Arrazubi, Virginia, Custodio, Ana, Fernández Montes, Ana, Diez, Marc, Hernandez, Raquel, Limón, María Luisa, Cano, Juana María, Vidal-Tocino, Rosario, Macias, Ismael, Visa, Laura, Martin Richard, Marta, Sauri, Tamara, Hierro, Cinta, Gil, Mireia, Cerda, Paula, Martínez Moreno, Elia, Martínez Lago, Nieves, Mérida-García, Antonio José, Gómez González, Lucía, García Navalón, Francisco Javier, Ruiz Martín, Maribel, Marín, Gema, López-López, Flora, Ruperez Blanco, Ana Belen, Fernández, Alejandro Francisco, Jimenez-Fonseca, Paula, Carmona-Bayonas, Alberto, and Alvarez-Manceñido, Felipe

Published
2024
Full Text
View/download PDF

2. One-year efficacy and safety of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: KYONAL study.

Author

Dols, Manuel Cobo, Zambrano, Carmen Beato, Cabezón-Gutiérrez, Luis, Chicas-Sett, Rodolfo, Blancas López-Barajas, María Isabel, García Navalón, Francisco Javier, Fírvida Pérez, José Luis, Bermúdez, Gala Serrano, Torres, Pilar Togores, Mingorance, Ignacio Delgado, Marín, Alexandra Giraldo, Oriol, Anna Librán, Lario, Alfredo Paredes, Mauriño, Pedro Sánchez, Gómez, Oliver Higuera, Muñoz, Diana Moreno, González, Ibone Huerta, Sanz-Yagüe, Almudena, and López, Begoña Soler

Published
2023
Full Text
View/download PDF

3. One-year efficacy and safety of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: KYONAL study

Author

Cobo Dols, Manuel, primary, Beato Zambrano, Carmen, additional, Cabezón-Gutiérrez, Luis, additional, Chicas-Sett, Rodolfo, additional, Blancas López-Barajas, María Isabel, additional, García Navalón, Francisco Javier, additional, Fírvida Pérez, José Luis, additional, Serrano Bermúdez, Gala, additional, Togores Torres, Pilar, additional, Delgado Mingorance, Ignacio, additional, Giraldo Marín, Alexandra, additional, Librán Oriol, Anna, additional, Paredes Lario, Alfredo, additional, Sánchez Mauriño, Pedro, additional, Higuera Gómez, Oliver, additional, Moreno Muñoz, Diana, additional, Huerta González, Ibone, additional, Sanz-Yagüe, Almudena, additional, and Soler López, Begoña, additional

Published
2021
Full Text
View/download PDF

4. One-year efficacy and safety of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: KYONAL study

Author

Cobo Dols, Manuel, Beato Zambrano, Carmen, Cabezón-Gutiérrez, Luis, Chicas-Sett, Rodolfo, Blancas López-Barajas, María Isabel, García Navalón, Francisco Javier, Fírvida Pérez, José Luis, Serrano Bermúdez, Gala, Togores Torres, Pilar, Delgado Mingorance, Ignacio, Giraldo Marín, Alexandra, Librán Oriol, Anna, Paredes Lario, Alfredo, Sánchez Mauriño, Pedro, Higuera Gómez, Oliver, Moreno Muñoz, Diana, Huerta González, Ibone, Sanz-Yagu¨e, Almudena, and Soler López, Begoña

Abstract

ObjectivesNaloxegol is a peripherally acting µ-opioid receptor antagonist (PAMORA) for treatment of opioid-induced constipation (OIC). The main objective was to analyse the long-term efficacy, quality of life (QOL) and safety of naloxegol in patients with cancer in a real-world study.MethodsThis one-year prospective study included patients older than 18 years, with active oncological disease who were under treatment with opioids for pain control and Karnofsky≥50 and OIC with inadequate response to treatment with laxative (s). All the patients received treatment with naloxegol according to clinical criteria. The main efficacy objectives were measured by the patient assessment of constipation QOL questionnaire (PAC-QOL), the PAC symptoms (PAC-SYM), the response rate at day 15, and months 1-3-6-12, and global QOL (EuroQoL-5D-5L).ResultsA total of 126 patients (58.7% males) with a mean age of 61.5 years (95% CI 59.4 to 63.7) were included. PAC-SYM and PAC-QOL total score and all their dimensions improved from baseline (p<0.0001). At 12 months, 77.8% of the patients were responders to naloxegol treatment. Global QOL was conserved from baseline. A total of 28 adverse reactions, mainly gastrointestinal were observed in 15.1% of the patients (19/126), being 75% (21) mild, 17.9% (5) moderate and 7.1% (2) severe. Most adverse reactions (67.9%) appeared the first 15 days of treatment.ConclusionThe results of this first long-term and real-world-data study in patients with cancer, showed the sustained efficacy and safety of naloxegol for the treatment of OIC in this group of patients.

Published
2023
Full Text
View/download PDF

5. Analysis of the efficacy and safety of naloxegol administered to patients with cancer and opioid-induced constipation with laxative-inadequate response: A real-world 12 months of follow-up study.

Author

Dols, Manuel Cobo, primary, Beato, Carmen, additional, Cabezon-Gutierrez, Luis, additional, Chicas Sett, Rodolfo, additional, Blancas, Isabel, additional, García Navalón, Francisco Javier, additional, Fírvida Pérez, José-Luis, additional, Serrano Bermúdez, Gala, additional, Togores, Pilar, additional, Delgado, Ignacio, additional, Giraldo-Marín, Alexandra, additional, Librán-Oriol, Anna, additional, Paredes Lario, Alfredo, additional, Sánchez Mauriño, Pedro, additional, Higuera, Oliver, additional, Moreno, Diana, additional, Jiménez-López, Antonio Javier, additional, Huerta-González, Ibone, additional, Sanz-Yagüe, Almudena, additional, and Soler, Begoña, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results